Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
filingDate |
2014-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2016-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2016534717-A |
titleOfInvention |
Chimeric receptors induce antibody-dependent cytotoxicity against a variety of tumors |
abstract |
The present invention relates to a chimeric receptor that binds to the Fc portion of a human immunoglobulin and delivers an activation signal. The chimeric receptor of the present invention may comprise the extracellular ligand binding domain of F158 FCGR3A or a high affinity V158 FCGR3A variant, the hinge and transmembrane domains of CD8α and the signaling domain of CD3ζ and 4-1BB. The chimeric receptor of the present invention has a high affinity for rituximab, trastuzumab, hu14.18K322A and other therapeutic antibodies and should help increase the effectiveness of antibody therapy against various cancers. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020533981-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017527310-A |
priorityDate |
2013-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |